Human infection due to recombinant vaccinia-rabies glycoprotein virus.
Rupprecht
C E
CE
Rabies Section, Centers for Disease Control and Prevention,  Atlanta, GA 30333, USA. cyr5@cdc.gov
Blass
L
L
Smith
K
K
Orciari
L A
LA
Niezgoda
M
M
Whitfield
S G
SG
Gibbons
R V
RV
Guerra
M
M
Hanlon
C A
CA
D000328:Adult; D000914:Antibodies, Viral / Q000097:blood; D000956:Antigens, Viral; D004279:DNA, Viral / Q000032:analysis; D005260:Female; D006023:Glycoproteins / Q000235:genetics* / Q000276:immunology; D006801:Humans; D017488:Hyperkeratosis, Epidermolytic / Q000150:complications*; D011247:Pregnancy; D011248:Pregnancy Complications; D011818:Rabies / Q000209:etiology* / Q000821:virology; D011819:Rabies Vaccines / Q000009:adverse effects*; D011820:Rabies virus / Q000235:genetics* / Q000276:immunology; D014616:Vaccinia virus; D014759:Viral Envelope Proteins / Q000235:genetics* / Q000276:immunology
D000914:Antibodies, Viral; D000956:Antigens, Viral; D004279:DNA, Viral; D006023:Glycoproteins; D011819:Rabies Vaccines; D014759:Viral Envelope Proteins; C064951:glycoprotein G, Rabies virus